Tresiba: payments to doctors
Payments that named Tresiba as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $7.2M
- Providers
- 33,831
- Transactions
- 140,142
- Average per transaction
- $52
The per-transaction average — $52 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 33,831 providers the average total is $214, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novo Nordisk | $7,105,945 | 98.4% |
| Novo Nordisk AS | $117,157 | 1.6% |